Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Yuviwel (navepegritide) is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
• In children aged 2 to 11 years with achondroplasia, navepegritide increased annualized growth velocity at week 52 with a least-squares mean treatment difference of 1.49 cm/year (95% CI, 1.05 to 1.93; P < .001).
• In the same population, skeletal outcomes showed improvements: tibial-femoral angle (least-squares mean difference −1.81 degrees; 95% CI, −3.16 to −0.47), mechanical axis deviation (−2.78 mm; 95% CI, −4.71 to −0.86), and fibula to tibia length ratio (−0.016; 95% CI, −0.024 to −0.008).
• In children younger than 5 years, physical functioning improved as measured by Achondroplasia Child Experience Measures-Physical Functioning (ACEM-Phys), with a least-squares mean difference of −11.1 (95% CI, −21.5 to −0.80).
• In children aged 2 to 11 years with achondroplasia, no serious adverse events were treatment-related, no deaths occurred, and there were no instances of symptomatic hypotension or fractures; injection site reactions were reported at low rates.
• No specific safety concerns or subgroup-specific adverse effects were identified beyond the general pediatric population (2 to 11 years).
• Children aged 2 to 11 years with achondroplasia (genetically confirmed) were the primary population, with stratification by age and gender; clinically relevant subgroup findings include children younger than 5 years demonstrating improvement in physical functioning (least-squares mean difference −11.1; 95% CI, −21.5 to −0.80).